KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Receivables (2016 - 2025)

Pacira BioSciences (PCRX) has 16 years of Receivables data on record, last reported at $124.1 million in Q4 2025.

  • For Q4 2025, Receivables rose 9.5% year-over-year to $124.1 million; the TTM value through Dec 2025 reached $124.1 million, up 9.5%, while the annual FY2025 figure was $124.1 million, 9.5% up from the prior year.
  • Receivables reached $124.1 million in Q4 2025 per PCRX's latest filing, up from $115.3 million in the prior quarter.
  • Across five years, Receivables topped out at $124.1 million in Q4 2025 and bottomed at $50.0 million in Q3 2021.
  • Average Receivables over 5 years is $95.8 million, with a median of $98.7 million recorded in 2022.
  • Peak YoY movement for Receivables: surged 87.04% in 2022, then grew 1.2% in 2023.
  • A 5-year view of Receivables shows it stood at $96.3 million in 2021, then increased by 2.16% to $98.4 million in 2022, then increased by 7.28% to $105.6 million in 2023, then increased by 7.34% to $113.3 million in 2024, then rose by 9.5% to $124.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $124.1 million in Q4 2025, $115.3 million in Q3 2025, and $114.4 million in Q2 2025.